Edwards Lifesciences favorable FDA panel priced into shares, says Deutsche Bank

Deutsche Bank believes the favorable FDA panel vote last night for Edwards Lifesciences' SAPIEN and FDA approval was already priced into shares. The firm raised its price target for Edwards Lifesciences to $80 from $75 but maintains a Hold rating on the stock.